CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.19 USD | +2.62% |
|
-6.68% | -55.11% |
| May. 15 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.25M | Capitalization | 492M |
|---|---|---|---|---|---|
| Net income 2024 * | -108M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 254M | Net cash position 2025 * | 173M | EV / Sales 2025 * | 51 x |
| P/E ratio 2024 * |
-4.82
x | P/E ratio 2025 * |
-4.57
x | Employees | 119 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | +2.62% | ||
| 1 week | -6.68% | ||
| 1 month | -17.89% | ||
| 3 months | -57.49% | ||
| 6 months | -36.39% | ||
| Current year | -55.11% |
1 week
9.72
11.20
1 month
9.7213.30
Current year
9.7226.35
1 year
9.5526.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
| Compliance Officer | - | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 19-02-18 | |
| Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 10.19 | +2.62% | 1,255,752 |
| 24-05-30 | 9.93 | -1.19% | 731,407 |
| 24-05-29 | 10.05 | -5.81% | 700,880 |
| 24-05-28 | 10.67 | -2.29% | 631,618 |
| 24-05-24 | 10.92 | -2.59% | 506,435 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
2024-06-03
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.19
USD
Average target price
33.56
USD
Spread / Average Target
+229.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.11% | 492M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- CABA Stock
